“Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.”, Lancet, vol. 391, no. 10118, pp. 309-318, 2018.
, “Care cascade structural intervention versus standard of care in the diagnosis and treatment of HIV in China: a cluster-randomized controlled trial protocol.”, BMC Health Serv Res, vol. 17, no. 1, p. 397, 2017.
, “Testing and linkage to HIV care in China: a cluster-randomised trial.”, Lancet HIV, vol. 4, no. 12, pp. e555-e565, 2017.
, “Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.”, Addiction, vol. 111, no. 4, pp. 695-705, 2016.
, “Loss to Follow-Up from HIV Screening to ART Initiation in Rural China.”, PLoS One, vol. 11, no. 10, p. e0164346, 2016.
, “NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.”, Contemp Clin Trials, vol. 50, pp. 253-64, 2016.
, “Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: an efficacy trial conducted in the real world.”, Contemp Clin Trials, vol. 33, no. 5, pp. 993-1002, 2012.
,